CD106抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD106 mouse mAb against COS7 (1), MCF-7 (2), HepG2 (3), and Hela (4) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD106 mouse mAb (green) and negative control (red).    

  
  

**Background of CD106 Antibody**

CD106. also known as Vascular Cell Adhesion Molecule-1 (VCAM-1), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on activated endothelial cells, certain immune cells (e.g., dendritic cells), and stromal cells. CD106 mediates leukocyte-endothelial adhesion by binding to integrin α4β1 (VLA-4) on immune cells, playing a critical role in inflammation, immune response, and leukocyte trafficking.

CD106 antibodies are tools used to detect or block this molecule in research and clinical contexts. In pathological conditions, upregulated CD106 expression is associated with chronic inflammation (e.g., atherosclerosis, rheumatoid arthritis) and cancer metastasis, where it facilitates tumor cell adhesion and extravasation. Studies using CD106 antibodies have elucidated its involvement in these processes, highlighting its potential as a therapeutic target. For instance, anti-CD106 strategies are explored to inhibit leukocyte infiltration in autoimmune diseases or disrupt tumor microenvironment interactions.

In experimental settings, CD106 antibodies are employed in flow cytometry, immunohistochemistry, and functional assays (e.g., adhesion inhibition). Additionally, CD106 is a marker for certain stem cells, such as mesenchymal stromal cells, where its expression correlates with immunomodulatory properties. Overall, CD106 antibodies serve as vital reagents for investigating vascular biology, inflammation, and regenerative medicine, bridging mechanistic insights to therapeutic development.